Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Novatarg Inc
Profile last edited on: 12/29/17      CAGE: 687Y1      UEI: J1FSU9JXELE1

Business Identifier: Drug develoment on tissue targeted cells for metabolic diseases and cancer
Year Founded
2009
First Award
2013
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2 Davis Drive
Durham, NC 27709
   (919) 406-4367
   ken@novatargtherapeutics.com
   www.novatarg.org
Location: Single
Congr. District: 04
County: Durham

Public Profile

Novatarg Inc. is a pharmaceutical company focused on the discovery of tissue-targeted medicines. The company designs and synthesizes small molecules that utilize specific transporters that allow our drugs to selectively enter target cells. The company's technology utilizies activation of AMPK through their tissue selective approach which provides improved efficacy and safety for the treatment of human cancers (ovarian and hepatocellular), type 2 diabetes (T2D) and hepatitis C (HCV). The firm's two focuses are 1. Transporter Dependent Drug Delivery (T3D) 2. A focus on the discovery and development of AMP-activated kinase (AMPK) activators.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
2
Conversion Rate
66.67%
Phase I Dollars
$956,339
Phase II Dollars
$4,507,988
Total Awarded
$5,464,327

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 2 NIH $3,240,695
Project Title: Liver Selective Ampk Activator to Treat Type 2 Diabetes
2016 2 NIH $1,998,632
Project Title: Kidney Selective AMPK Activators to Treat Polycystic Kiney Disease
2014 1 NIH $225,000
Project Title: Novel and Selective Ampk Activator for the Treatment of Hepatocellular Carcinoma

Key People / Management

  Ken W Batchelor -- President and CEO

  Jeff Cobb -- VP Drug Discovery

  Nick Livingston -- VP Biology

Company News

There are no news available.